STOCK TITAN

Aspira Women's Health Inc. - AWH STOCK NEWS

Welcome to our dedicated page for Aspira Women's Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.

Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.

One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.

In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.

The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.

Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.

The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.

Rhea-AI Summary

Aspira Women’s Health Inc. (NASDAQ: AWH) announced promising initial clinical data for its blood-based test OVASight, aimed at assessing the risk of ovarian cancer in women with suspected benign pelvic masses. In a low prevalence population (3.8%), OVASight achieved 89% specificity, 91% sensitivity, and a negative predictive value of 99.6%. These results outperform traditional CA-125 testing in early-stage disease. The data was released during the American Society of Clinical Oncology (ASCO) 2021 virtual meeting, emphasizing the company's commitment to improving women's health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.29%
Tags
none
-
Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its participation in the William Blair Growth Stock Conference from June 1-3, 2021. The company will present on June 3 at 9:00 am ET. Aspira focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment and pelvic diseases. Their product portfolio includes OVA1® plus and ASPIRA GenetiX™ testing, aimed at improving gynecologic health outcomes. For more details, visit their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.71%
Tags
conferences
-
Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) reported Q1 2021 financial results, highlighting a 23% increase in total product and genetics revenue to $1.496 million. OVA1plus tests performed rose by 3% to 3,775. The company initiated a large prospective clinical study with Northwell Health and established a significant commercial agreement with a major women's health network. However, R&D expenses surged by 121% compared to Q1 2020, indicating increased investment in product development. The firm ended the quarter with approximately $59.4 million in cash.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
Rhea-AI Summary

Aspira Women’s Health (Nasdaq: AWH) announced the analytical and initial clinical validation of its OVASight™ blood-based biomarker test for assessing ovarian malignancy risk in women with adnexal masses. The abstract detailing this test will be presented at the ASCO 2021 meeting from June 4-8. The OVASight™ test showcases a high negative predictive value, enhancing clinician confidence in monitoring suspected benign masses. The product is expected to be available in Q4 2021, aiming to replace the CA-125 test.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
Rhea-AI Summary

Aspira Women’s Health (Nasdaq: AWH) announced a new clinical study focused on ovarian cancer risk detection, in partnership with Northwell Health. The study aims to enroll over 600 women with adnexal masses and more than 2000 high-risk patients, utilizing both CA125 and the proprietary OVASight algorithm. The primary goal is to validate the algorithm for serial monitoring, while the secondary goal is to develop a proteogenomic test for early-stage ovarian cancer detection. This initiative reinforces Aspira’s commitment to enhancing diagnostic options for women's health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) announced the appointment of Greg Richard as the new Head of Corporate Strategy, Reimbursement, and Managed Care, reporting to President and CEO Valerie Palmieri. Greg Richard brings over 20 years of experience in developing strategies for diagnostics coverage and reimbursement. His role includes leading corporate strategy, enhancing reimbursement processes, and managing the Revenue Cycle Management team. Aspira aims to improve women’s health outcomes, especially concerning ovarian cancer detection and risk assessment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
management
Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) will announce its first-quarter financial results for the period ending March 31, 2021, on May 13, 2021, after market close. A conference call and webcast will be held at 4:30 p.m. ET the same day, with domestic and international dial-in numbers provided for investor participation.

The company focuses on innovative testing options and bio-analytical solutions aimed at improving women's health outcomes, including addressing ethnic disparities in ovarian cancer risk assessment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
conferences earnings
-
Rhea-AI Summary

Aspira Women’s Health Inc. (AWH) announced its Q4 2020 financial results, revealing a year of stock price appreciation despite pandemic challenges. Total product and genetics revenue increased by 11% year-over-year to $1.4 million, with a 7% rise in total units sold. Notably, the company accelerated the launch of its OVASight test to Q4 2021. New York Medicaid coverage expansion could increase reach to 1.5 million women. However, R&D expenses surged significantly, reflecting increased investment in product development. Aspira concluded 2020 with $16.6 million in cash.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
-
Rhea-AI Summary

Aspira Women’s Health (Nasdaq: AWH) has signed an agreement with Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University Lodz to develop a high-risk early detection test for ovarian cancer using novel microRNA technology. This collaboration aims to enhance early detection, which significantly increases survival rates, as ovarian cancer has a high mortality rate. The initiative reflects Aspira's commitment to women's health and creating innovative testing options, particularly in assessing ovarian cancer risk.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) will announce its financial results for Q4 and full year 2020 on March 25, 2021, after market close. An investor conference call and webcast is scheduled for 4:30 p.m. ET on the same day. The company focuses on innovative testing options in women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. Its FDA-cleared products OVA1® and OVERA® assist in evaluating ovarian malignancy risk. Aspira is committed to improving gynecologic health outcomes and addressing ethnic disparities in healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
conferences earnings

FAQ

What is the current stock price of Aspira Women's Health (AWH)?

The current stock price of Aspira Women's Health (AWH) is $0.7401 as of November 14, 2024.

What is the market cap of Aspira Women's Health (AWH)?

The market cap of Aspira Women's Health (AWH) is approximately 12.4M.

What is Aspira Women's Health Inc. known for?

Aspira Women's Health Inc. is known for developing and commercializing noninvasive diagnostic tests for gynecologic diseases, particularly ovarian cancer.

What products does Aspira offer?

Aspira offers OvaSuite, which includes OvaWatch and Ova1Plus. These are blood tests designed to assess the risk of ovarian cancer in women with adnexal masses.

How effective is OvaWatch?

OvaWatch has a negative predictive value of 99%, making it highly effective in assessing ovarian cancer risk in women with indeterminate or benign adnexal masses.

What is Ova1Plus?

Ova1Plus is a combination of two FDA-cleared tests, Ova1® and Overa®, designed to assess the risk of ovarian malignancy in women planned for surgery.

What recent achievements has Aspira made?

Aspira has recently published significant clinical studies, secured Anthem Blue Cross payer coverage, and reduced operational cash use while increasing revenues and test volumes.

What is EndoCheck?

EndoCheck is the first-ever noninvasive test developed by Aspira to identify endometriomas, a common form of endometriosis.

How has Aspira performed financially recently?

In 2023, Aspira reduced its operational cash use, increased revenues, and achieved key market access milestones. They also raised $5.5 million through a direct offering and private placement.

Who leads Aspira Women's Health Inc.?

Aspira is led by CEO Nicole Sandford, who has guided the company through significant growth and innovation in women's health diagnostics.

What is OvaMDx?

OvaMDx is an in-development test that combines microRNA and protein biomarkers with patient data to enhance the sensitivity and specificity of ovarian cancer risk assessments.

How does Aspira's test pipeline address women's health issues?

Aspira's test pipeline, including EndoCheck and OvaMDx, aims to provide noninvasive diagnostic solutions for ovarian cancer and endometriosis, improving care and outcomes for millions of women.

Aspira Women's Health Inc.

Nasdaq:AWH

AWH Rankings

AWH Stock Data

12.37M
16.06M
30.94%
8.62%
2.78%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
AUSTIN